会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 7. 发明授权
    • Naphtho- and dihydrobenzo-thiophene derivatives as cytotoxic antitumor agents
    • 萘并 - 二氢苯并噻吩衍生物作为细胞毒性抗肿瘤剂
    • US06337346B1
    • 2002-01-08
    • US09651357
    • 2000-08-30
    • Kuo-Hsiung LeeSheng-Chu Kuo
    • Kuo-Hsiung LeeSheng-Chu Kuo
    • A61K3138
    • C07D495/04C07D333/74
    • Compounds useful as cytotoxic agents are selected from the group consisting of compounds of Formula I and compounds of Formula II: wherein: R1, R2, R3 and R4 are each independently selected from the group consisting of: hydrogen, alkyl, carboxy, alkoxy, hydroxyalkyl, alkylcarbonyl; alkylcarbonyloxy; alkyl substituted with alkylcarbonyloxy, thiophenylcarbonyl; nitro and cyano; thiophenyl and thiophenylthiophenyl, each of which may be unsubstituted or substituted with alkyl, carboxy, alkoxy, hydroxyalkyl, alkylcarbonyl; alkylcarbonyloxy; alkyl substituted with alkylcarbonyloxy, nitro or cyano; subject to the proviso that at least one of R1, R2, R3 and R4 is not hydrogen; A1 and A2 are each selected from the group consisting of: ═O, alkyl, alkoxy, and alkylcarbonyloxy; and the pharmaceutically acceptable salts thereof. When A1 and A2 are ═O, the center ring has only two, and not three, double bonds.
    • 可用作细胞毒性剂的化合物选自式I化合物和式II化合物:其中:R 1,R 2,R 3和R 4各自独立地选自氢,烷基,羧基,烷氧基,羟基烷基 ,烷基羰基; 烷基羰氧基 被烷基羰基氧基取代的烷基,硫代苯基羰基; 硝基和氰基; 硫代苯基和噻吩硫基苯基,其各自可以是未取代的或被烷基,羧基,烷氧基,羟烷基,烷基羰基取代; 烷基羰氧基 被烷基羰基氧基,硝基或氰基取代的烷基; 条件是R 1,R 2,R 3和R 4中的至少一个不是氢; A1和A2各自选自:= O,烷基,烷氧基和烷基羰基氧基; 及其药学上可接受的盐。 当A1和A2为= O时,中心环只有两个,而不是三个双键。
    • 8. 发明授权
    • Naphthoquinone antitumor compound and method
    • 萘醌类抗肿瘤化合物及方法
    • US06174918B1
    • 2001-01-16
    • US09126624
    • 1998-07-30
    • Kuo-Hsiung LeeSheng-Chu KuoToshiro Ibuka
    • Kuo-Hsiung LeeSheng-Chu KuoToshiro Ibuka
    • A61K3121
    • C07D235/02C07C233/32C07C233/42C07C233/43C07C233/44C07C233/76C07C2602/10
    • The invention provides 1,4-naphthoquinone compounds and a method for inhibiting tumor cell growth in a subject by administering such compounds. The compounds are represented by the structures: where R1 is lower alkyl, halogenated lower alkyl, phenyl, benzyl, phenethyl, or —(CH2)mCOOX, where m is 2 or 3 and X is H, methyl, or ethyl; R2 is halo or NHY, where Y is hydrogen, loweralkyl, halogenated lower alkyl, hydroxylated lower alkyl, lower dialkylaminoalkyl, phenyl, benzyl, or phenethyl; R3 is lower alkyl, halogenated lower alkyl, phenyl, benzyl, phenethyl, or —(CH2)mCOOX, where m and X are as defined for R1 above; and R4 is hydrogen, lower alkyl, lower aminoalkyl, halogenated lower alkyl, phenyl, benzyl, or phenethyl.
    • 本发明提供1,4-萘醌化合物和通过施用这些化合物来抑制受试者的肿瘤细胞生长的方法。 化合物由以下结构表示:其中R1是低级烷基,卤代低级烷基,苯基,苄基,苯乙基或 - (CH2)mCOOX,其中m是2或3,X是H,甲基或乙基; R2是卤素或NHY,其中Y是氢,低级烷基,卤代低级烷基,羟基化的低级烷基,低级二烷基氨基烷基,苯基,苄基或苯乙基; R3是低级烷基,卤代低级烷基,苯基,苄基,苯乙基或 - (CH2)mCOOX,其中m和X如上述R1所定义; 和R4是氢,低级烷基,低级氨基烷基,卤代低级烷基,苯基,苄基或苯乙基。
    • 9. 发明申请
    • SYNTHESIS AND ANTICANCER ACTIVITY OF ARYL AND HETEROARYL-QUINOLIN DERIVATIVES
    • 芳基和喹啉衍生物的合成和反应活性
    • US20120015908A1
    • 2012-01-19
    • US13181978
    • 2011-07-13
    • Sheng-Chu KuoKuo-Hsiung LeeLi-Jiau HuangLi-Chen ChouTian-Shung WuTzong-Der WayJing-Gung ChungJai-Sing YangChi-Hung HuangMeng-Tung Tsai
    • Sheng-Chu KuoKuo-Hsiung LeeLi-Jiau HuangLi-Chen ChouTian-Shung WuTzong-Der WayJing-Gung ChungJai-Sing YangChi-Hung HuangMeng-Tung Tsai
    • A61K31/675A61K31/47C07D491/056A61K31/4741C07F9/60A61P35/00A61K31/5377C07D405/14A61K31/4709C07D413/10C07D401/10C07D215/233C07D413/14
    • C07D493/04C07D215/22C07D215/233C07D215/38C07D401/04C07F9/60C07F9/65583C07F9/6561
    • A compound of Formula I is disclosed as follows: or a pharmaceutically acceptable salt, prodrug, solvate, or metabolite thereof, wherein R is hydrogen, P(═O)(OH)2, P(═O)(O(C1-C18)alkylene(C6-C20)aryl)2, P(═O)(OH)(OM), P(═O)(OM)2, P═O(O2M), S(═O)(OH)2, S(═O)(O(C1-C18)alkylene(C6-C20)aryl)2, S(═O)(OH)(OM), S(═O)(OM)2; M is a monovalent or divalent metal ion, or alkylammonium ion; W is (C6-C20)aryl, (C6-C20)heteroaryl, (C1-C18)alkyl(C6-C20)aryl, (C1-C18)alkyl(C6-C20)heteroaryl, hydroxy(C6-C20)aryl, hydroxy(C6-C20)heteroaryl, (C1-C18)alkoxy(C6-C20)aryl, (C1-C18)alkoxy(C6-C20)heteroaryl, (C1-C18)alkylenedioxy(C6-C20)aryl, (C1-C18)alkylenedioxy(C6-C20)heteroaryl, halo(C6-C20)aryl, halo(C6-C20)heteroaryl, (C1-C18)alkylamino(C6-C20)aryl, (C1-C18)alkylamino(C6-C20)heteroaryl, (C1-C18)cycloalkylamino(C6-C20)aryl, or (C1-C18)cycloalkylamino(C6-C20)heteroaryl, and their OR8 substutes; R5 is (C1-C18alkoxy, hydrogen, hydroxyl, O—(C1-C18)alkyl(C6-C20)aryl, halo or OR8, or R5 and R6 are (C1-C18)dioxy provided that R7 is hydrogen; R6 is hydroxyl, O—(C1-C18)alkyl(C6-C20)aryl, halo or ORR, (C1-C18)alkoxy, (C1-C18)alkylamino, or (C1-C18)cycloalkylamino, or R6 and R7 are (C1-C18)dioxy provided that R5 is hydrogen; R7 is hydrogen, halo or OR8, hydroxyl, or O—(C1-C18)alkyl(C6-C20)aryl; and R8 is P(═O)(OH)2, P(═O)(O(C1-C18)alkyl(C6-C20)aryl)2, P(═O)(OH)(OM), or P(═O)(OM)2, P═O(O2M).
    • 式I的化合物公开如下:或其药学上可接受的盐,前药,溶剂合物或代谢物,其中R是氢,P(= O)(OH)2,P(= O)(O(C 1 -C 18) )亚烷基(C 6 -C 20)芳基)2,P(= O)(OH)(OM),P(= O)(OM)2,P = O(O 2 M) S(ΟO)(O(C1-C18)亚烷基(C6-C20)芳基)2,S(═0)(OH)(OM),S(ΟO)(OM) M是一价或二价金属离子或烷基铵离子; W是(C 6 -C 20)芳基,(C 6 -C 20)杂芳基,(C 1 -C 18)烷基(C 6 -C 20)芳基,(C 1 -C 18)烷基(C 6 -C 20) 羟基(C 6 -C 20)杂芳基,(C 1 -C 18)烷氧基(C 6 -C 20)芳基,(C 1 -C 18)烷氧基(C 6 -C 20)杂芳基,(C 1 -C 18)亚烷基二氧基 C 1 -C 20烷基氨基(C 6 -C 20)芳基,(C 1 -C 20)芳基,(C 1 -C 20)芳基, 杂芳基,(C1-C18)环烷基氨基(C6-C20)芳基或(C1-C18)环烷基氨基(C6-C20)杂芳基及其OR8分子; R5是(C1-C18烷氧基,氢,羟基,O-(C1-C18)烷基(C6-C20)芳基,卤素或OR8或R5和R6是(C1-C18)二氧基,条件是R7是氢; R6是羟基 ,(C 1 -C 18)烷基(C 6 -C 20)芳基,卤素或ORR,(C 1 -C 18)烷氧基,(C 1 -C 18)烷基氨基或(C 1 -C 18)环烷基氨基或R 6和R 7为 其中R 5为氢,R 7为氢,卤素或OR 8,羟基或O-(C 1 -C 18)烷基(C 6 -C 20)芳基; R 8为P(= O)(OH)2,P (O)(O(C1-C18)烷基(C6-C20)芳基)2,P(= O)(OH)(OM)或P(= O)(OM)2,P = O(O2M)。